. Author manuscript; available in PMC: 2012 Sep 28.

Published in final edited form as: Clin Cancer Res. 2010 Nov 24;17(3):514–524. doi: 10.1158/1078-0432.CCR-10-1617

Table 2.

Median effects of Dasatinib and PHA665752 as Single Agents and in Combination

Cell line	Single agent, IC₅₀		Combination, IC₅₀		Combination Index Simulations	Interpretation

	Dasatinib (nM)	PHA665752 (μM)	Dasatinib (nM)	PHA665752 (μM)	F_a = 0.5
Tu167	45 ± 7.7	6.8 ± 2.1	20 ± 6.6	1.6 ± 0.53	0.68 ± 0.15	Synergistic
TR146	67 ± 2.3	2.6 ± 1.0	27 ± 13	0.53 ± 0.27	0.60 ± 0.22	Synergistic
UMSCC14a	186 ± 15	1.9 ± 0.7	28 ± 18	0.57 ± 0.37	0.44 ± 0.26	Synergistic
Osc19	312 ± 36	8.7 ± 4.9	107 ± 39	1.1 ± 0.39	0.47 ± 0.12	Synergistic
Tu167R2	803 ± 189	22 ± 1.4	268 ± 86	1.1 ± 0.34	0.38 ± 0.09	Synergistic
Tu167R1	>1000	6.5 ± 2.2	316 ± 129	1.3 ± 0.50	0.41 ± 0.13	Synergistic
Tu138	>5000	2.1 ± 0.3	148 ± 19	1.5 ± 0.02	0.72 ± 0.07	Synergistic

Data presented as mean ± standard deviation.